Bristol-Myers Squibb Co. said Thursday its experimental drug brivanib didn't improve overall survival in liver-cancer patients in a late-stage clinical trial. ❋ Peter Loftus (2011)
Bristol said a separate study is testing brivanib as a potential first-line treatment in newly diagnosed liver-cancer patients. ❋ Peter Loftus (2011)
AG, the U. K.'s health-care cost-effectiveness watchdog Wednesday confirmed that Britain's state health system shouldn't pay for the German company's liver-cancer drug Nexavar, "because its high cost could not be justified by its marginal benefit." ❋ Unknown (2010)
Drug developer Delcath Systems jumped 2.08, or 19%, to 12.93, after Phase III of a National Cancer Institute-led clinical trial of its liver-cancer treatment exceeded its primary endpoint expectations. ❋ Unknown (2010)
In other research, when several fruits were tested ‘in vitro’ on human liver-cancer cells, apple rated third in antiproliferation activity. ❋ Bryanna Clark Grogan (2008)
Yesterday's move came after the pharmaceutical company swung to a third-quarter profit of $555,000, or 1 cent a share, and noted a jump in revenue for Nexavar, a kidney - and liver-cancer therapy. ❋ Unknown (2007)
Italian surgeons are treating liver-cancer by removing the organ, irradiating it and then re-implanting it -- and it works! ❋ Unknown (2002)
Dr. Cherdchai Tontisirin, a surgeon in Khon Kaen who has operated on liver-cancer patients, blamed the Thai government for the persistence of the disease. ❋ Unknown (2011)
Known as bile-duct cancer, it is relatively uncommon in most parts of the world but represents the majority of the 70 liver-cancer deaths a day in Thailand, according to Dr. Banchob Sripa, the head of the tropical-disease research laboratory at nearby Khon Kaen University. ❋ Unknown (2011)
Study shows promising basis for development of effective liver-cancer screening test ❋ Editors (2010)
But that might be about to change, according to Dr. Claus Fimmel, a hepatologist who is involved in an international study of a protein that is shaping up as a promising basis for the development of an effective liver-cancer screening test for high-risk patients. ❋ Unknown (2010)
The biotech company Alnylam announced in June that its drug ALN-VSP cut off blood flow to 62 percent of liver-cancer tumors in those 19 patients, by triggering a rarely used defense mechanism in the body to silence cancerous genes. ❋ Unknown (2010)
In Asia, Japan is handling liver-cancer issues, India those linked to that of the mouth, while China is making progress in deciphering stomach cancer. ❋ Unknown (2009)
His results with these patients have been about the same as those with other liver-cancer sufferers, about 70 percent of whom have healthy organs five years after surgery, he said. ❋ Unknown (2009)
Nexavar for liver-cancer patients, because it costs too much -- $4,850 per month. ❋ Unknown (2009)
